ReviewReviews in endocrine & metabolic disorders2025
Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis.
Review in Reviews in endocrine & metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Enzyme-Activated Self-Assembling Peptides Mimicking Adiponectin Multimers for Nonalcoholic Fatty Liver Disease Therapy.ACS central science · 2026Article
- Docosahexaenoic acid (DHA) alleviates hepatic lipid deposition in dairy cows during the transition period: an integrated in vitro and in vivo study.Journal of animal science and biotechnology · 2025Article
- Nano-Enhanced Diets: Advancing Metabolic Dysfunction-Related Steatotic Liver Disease (MASLD) - A Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of metabolic dysfunction-associated steatotic liver disease (MASLD), and its progression to metabolic dysfunction-associated steatohepatitis (MASH), is triggered and aggravated by obesity and related metabolic diseases. Hence, therapeutic strategies for obesity and diabetes are employed in the clinical management of MASLD and MASH. However, most of the antiobesity and antidiabetic drugs have been withdrawn from the market due to a lack of sustainable drug effects and undesirable side effects. Prior to the approval of resmetirom by the United States Food and Drug Administration in 2024, there were no specific treatments for MASLD and MASH. Therefore, this stresses the importance of developing improved and effective disease-specific treatment strategies to combat MASLD and MASH. MASLD and MASH are characterized by hepatocyte damage, chronic low-grade systemic inflammation, and abnormalities in lipid metabolism. Inflammation and oxidative stress are key mediators of high-fat diet-induced steatohepatitis and obesity. Identifying biomarkers involved in these processes could aid in the development of targeted treatment for MASLD and MASH. In this review, targeted treatment strategies for obesity are discussed in relation to the possibility of the same being used in obesity-related steatotic liver diseases (SLDs).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.